Hydroxyurea for Children with Sickle Cell Disease
Section snippets
An ideal drug for sickle cell disease?
Hydroxyurea may be an ideal therapeutic agent for use in children with SCD. It has excellent bioavailability after oral administration; requires only once-daily dosing, which improves medication adherence; has few if any immediate side effects; has predictable hematologic toxicities that are dose dependent, transient, and reversible; and has potential benefits against multiple pathophysiologic mechanisms of SCD. Although several therapeutic agents currently under development address specific
Clinical experience
Preclinical studies in anemic cynomolgus monkeys showed that hydroxyurea increased HbF levels.33 Pilot trials in patients with SCD demonstrated that hydroxyurea also increased HbF in humans and caused little short-term toxicity.29, 30, 31, 32 These proof-of-principle experiments were critical first steps toward an important multicenter phase I/II trial involving adults with HbSS, which identified the short-term efficacy and toxicities of hydroxyurea used at maximum tolerated dose (MTD).32
Practical considerations
Hydroxyurea therapy cannot be prescribed, monitored, and adjusted properly according to exact and specific written guidelines. Instead, optimal treatment with hydroxyurea (as with many other medications) requires careful attention to the details of each patient's treatment response; such individualized therapy often involves as much art as science. The following sections represent the distillation of a combined 25 years of experience with hydroxyurea (>300 treated children), but none of the
Summary
Hydroxyurea is a powerful therapeutic agent with proved laboratory and clinical efficacy for children with SCD. Although there are important questions regarding its long-term efficacy and safety, hydroxyurea has the potential to ameliorate many of the signs and symptoms of the disease. Ongoing clinical trials will help answer questions about the proper clinical indications for its use and, in particular, its ability to prevent organ damage and preserve organ function and long-term safety.
Acknowledgments
The authors thank Nicole A. Mortier, MHS PA-C, and William H. Schultz, MHS PA-C, for years of experience and dedication to treating children with SCD. We appreciate their insights and advice regarding the optimal use of hydroxyurea in this patient population.
References (72)
- et al.
Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of sickle cell anemia
Blood
(1984) - et al.
Relationship of clinical severity to packed cell rheology in sickle cell anemia
Blood
(1991) Fetal hemoglobin, sickling, and sickle cell disease
Adv Pediatr
(1990)Increased HbF in adult life
Baillieres Clin Haematol
(1993)Fetal haemoglobin in homozygous sickle cell disease
Clin Haematol
(1975)- et al.
F-cells in the adult: normal values and levels in individuals with hereditary and acquired elevations of Hb F
Blood
(1975) - et al.
Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?
Blood
(1984) - et al.
5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia
Blood
(1983) - et al.
Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia
Blood
(2002) - et al.
2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia
Blood
(2000)
Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease
Blood
Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease
Blood
Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate
Blood
The role of hydroxyurea in the management of sickle cell disease
Blood Rev
Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production
Blood
Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia
Blood
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia
Blood
Rat liver-mediated metabolism of hydroxyurea to nitric oxide
Free Radic Biol Med
Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group
Blood
Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study
J Pediatr
Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy
Blood
Hydroxyurea therapy in children severely affected with sickle cell disease
J Pediatr
Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia
J Pediatr
Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial
Blood
Five years of experience with hydroxyurea in children and young adults with sickle cell disease
Blood
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease
Blood
A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia
J Pediatr
Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study
Blood
Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia
Blood
Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease
Blood
Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy
J Pediatr
Efficacy of hydroxyurea to prevent organ damage in young children with sickle cell anemia
Blood
A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy
Blood
Pain in sickle cell disease. Rates and risk factors
N Engl J Med
The painful crisis of homozygous sickle cell disease. A study of the risk factors
Arch Intern Med
Sickle cell anemia: beta s-gene-cluster haplotypes as prognostic indicators of vital organ failure
Semin Hematol
Cited by (0)
A version of this article was previously published in the Pediatric Clinics of North America, 55:2.
Dr. Heeney is supported by NIH K12 HL087164 and U54 HL070819. Dr. Ware is supported by U54 HL070590, U01 HL078787, N01 HB 07155, and American Syrian Lebanese Associated Charities.